<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: Currently ", fill: "#dda0dd"},
{source: "5: Currently ", target: "5: products approved", fill: "#dda0dd"},
{source: "5: products approved", target: "5: commercial sale", fill: "#dda0dd"},
{source: "5: Currently ", target: "6: generate revenue depends heavily on", fill: "#836953"},
{source: "6: generate revenue depends heavily on", target: "6: demonstration", fill: "#836953"},
{source: "6: demonstration", target: "6: Phase IIIa and Phase IIb ", fill: "#836953"},
{source: "6: Phase IIIa and Phase IIb ", target: "6: clinical trials", fill: "#836953"},
{source: "6: clinical trials", target: "6: product candidates", fill: "#836953"},
{source: "6: product candidates", target: "6: Atiprimod ", fill: "#836953"},
{source: "6: Atiprimod ", target: "6: advanced carcinoid cancer", fill: "#836953"},
{source: "6: advanced carcinoid cancer", target: "6: acute leukemia respectively", fill: "#836953"},
{source: "6: acute leukemia respectively", target: "6: effective", fill: "#836953"},
{source: "6: effective", target: "6: successful development", fill: "#836953"},
{source: "6: successful development", target: "6: regulatory approvals", fill: "#836953"},
{source: "6: regulatory approvals", target: "6: with respect", fill: "#836953"},
{source: "6: with respect", target: "6: indications", fill: "#836953"},
{source: "6: indications", target: "6: successful commercialization", fill: "#836953"},
{source: "6: successful commercialization", target: "6: market acceptance", fill: "#836953"},
{source: "6: generate revenue depends heavily on", target: "7: candidates", fill: "#592720"},
{source: "7: candidates", target: "7: additional", fill: "#592720"},
{source: "7: additional", target: "7: evaluation", fill: "#592720"},
{source: "7: evaluation", target: "7: regulatory", fill: "#592720"},
{source: "7: regulatory", target: "7: significant", fill: "#592720"},
{source: "7: significant", target: "7: investment", fill: "#592720"},
{source: "7: candidates", target: "10: successfully", fill: "#808000"},
{source: "10: successfully", target: "10: commercialize", fill: "#808000"},
{source: "10: successfully", target: "START_HERE", fill: "#808000"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Ask for protection</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of which 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, with the winner qualifying for the challenger's spot against the defending champion Magnus Carlsen in the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CALLISTO PHARMACEUTICALS INC      ITEM 1A  RISK FACTORS       You <font color="blue">should carefully</font> consider the <font color="blue">following risk factors</font> and the other     information included <font color="blue">herein as well as</font> the information included in other     reports and filings made with the SEC before investing in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If any of the <font color="blue">following risks actually</font> occurs, our business, financial     condition or results of <font color="blue"><font color="blue">operations</font> could</font> be harmed</td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our     <font color="blue">common stock</font> could decline due to any of these risks, and you may lose part     or all of your <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR BUSINESS       WE ARE AT AN EARLY STAGE OF DEVELOPMENT AS A COMPANY, CURRENTLY HAVE NO     SOURCE OF REVENUE AND MAY NEVER BECOME PROFITABLE        We are a <font color="blue"><font color="blue">development</font> stage bio<font color="blue">pharmaceutical</font> company</font></td>
    </tr>
    <tr>
      <td>Currently, we have no     <font color="blue">products approved</font> for <font color="blue">commercial sale</font> and, to date, we have not generated     any revenue</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue"><font color="blue">generate revenue</font> depends heavily on</font>:         ·       <font color="blue">demonstration</font> in Phase I/IIa and Phase IIb <font color="blue">clinical trials</font> that our two     <font color="blue">product <font color="blue">candidates</font></font>, <font color="blue">Atiprimod </font>for the treatment of relapsed <font color="blue">multiple myeloma</font>     and <font color="blue"><font color="blue">advanced carcinoid</font> cancer</font> and L-<font color="blue">Annamycin </font>for the treatment of relapsed     <font color="blue">acute leukemia</font>, <font color="blue">respectively</font>, are safe and <font color="blue">effective</font>;         ·       the <font color="blue">successful <font color="blue">development</font></font> of our other <font color="blue">product <font color="blue">candidates</font></font>;         ·       our ability to seek and obtain <font color="blue"><font color="blue">regulatory</font> approvals</font>, including <font color="blue">with respect</font>     to the <font color="blue">indications</font> we are seeking;         ·       the <font color="blue">successful <font color="blue">commercialization</font></font> of our <font color="blue">product <font color="blue">candidates</font></font>; and         ·       <font color="blue">market <font color="blue">acceptance</font></font> of our products</td>
    </tr>
    <tr>
      <td>All of our existing <font color="blue">product <font color="blue">candidates</font></font> will require extensive <font color="blue">additional</font>     clinical <font color="blue">evaluation</font>, <font color="blue">regulatory</font> review, <font color="blue">significant</font> marketing efforts and     substantial <font color="blue">investment</font> before they could <font color="blue">provide us with</font> any revenue</td>
    </tr>
    <tr>
      <td>For     example, <font color="blue">Atiprimod </font>for the treatment of <font color="blue"><font color="blue">multiple myeloma</font> entered</font> Phase I/IIa     <font color="blue">clinical trials</font> in May 2004 and L-<font color="blue">Annamycin </font>for the treatment of acute     leukemia  entered  <font color="blue">clinical trials</font> in <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>Our other product     <font color="blue">candidates</font>  are  in preclinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>As a result, if we do not     <font color="blue">successfully</font> develop and <font color="blue">commercialize</font> <font color="blue">Atiprimod </font>or L-Annamycin, we will be     unable  to  generate  any revenue for many years, if at all</td>
    </tr>
    <tr>
      <td>We do not     anticipate that we will <font color="blue">generate revenue</font> for <font color="blue">several years</font>, at the earliest,     or that we will achieve <font color="blue">profitability</font> for <font color="blue">at least <font color="blue">several years</font></font> after     <font color="blue">generating</font>  material  revenue, if at all</td>
    </tr>
    <tr>
      <td>If we are unable to generate     revenue, we will not become profitable, and we may be unable to continue our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>WE HAVE INCURRED SIGNIFICANT LOSSES SINCE INCEPTION AND ANTICIPATE THAT WE     WILL INCUR CONTINUED LOSSES FOR THE FORESEEABLE FUTURE            As  of  <font color="blue">December </font> 31,  2005 and 2004, we had an <font color="blue">accumulated deficit</font> of     dlra45cmam140cmam654 and dlra33cmam361cmam197, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We incurred a net loss of dlra11cmam779cmam457,     dlra7cmam543cmam467 and dlra13cmam106cmam247 for the <font color="blue">twelve months</font> ended <font color="blue">December </font>31, 2005,     2004 and 2003, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>These losses, among other things, have had and     <font color="blue">will continue</font> to have an adverse effect on our <font color="blue">stockholders</font> &amp;apos  equity and     working capital</td>
    </tr>
    <tr>
      <td>We expect to incur <font color="blue">significant</font> and increasing operating     losses for the <font color="blue"><font color="blue">next <font color="blue">several years</font></font> as</font> we expand our research and <font color="blue">development</font>,     continue our <font color="blue">clinical trials</font> of <font color="blue">Atiprimod </font>for the treatment of multiple     myeloma and <font color="blue"><font color="blue">advanced carcinoid</font> cancer</font>, continue and initiate our clinical     trials of L-<font color="blue">Annamycin </font>for the treatment of <font color="blue"><font color="blue">acute leukemia</font>s</font>, acquire or     license <font color="blue">technologies</font>, advance our other <font color="blue">product <font color="blue">candidates</font></font> into clinical     <font color="blue">development</font>, seek <font color="blue">regulatory</font> approval and, if we receive FDA approval,     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">numerous risks</font> and <font color="blue">uncertainties</font>     <font color="blue">associated with</font> our product <font color="blue">development</font> efforts, we are unable to predict     the extent of any <font color="blue">future losses</font> or when we <font color="blue">will become profitable</font>, if at     all</td>
    </tr>
    <tr>
      <td>If we are unable to achieve and then maintain <font color="blue">profitability</font>, the market     value of our <font color="blue">common stock</font> will likely decline</td>
    </tr>
    <tr>
      <td>OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM HAS EXPRESSED DOUBT ABOUT     OUR ABILITY TO CONTINUE AS A GOING CONCERN, WHICH MAY HINDER OUR ABILITY TO     OBTAIN FUTURE FINANCING           Our <font color="blue">consolidated <font color="blue">financial statements</font> as</font> of <font color="blue">December </font>31, 2005 have been     prepared under the <font color="blue">assumption</font> that we <font color="blue">will continue</font> as a going concern for     the  year  ending <font color="blue">December </font>31, 2006</td>
    </tr>
    <tr>
      <td>Our in<font color="blue">dependent</font> registered public     <font color="blue">accounting firm</font> has issued a report dated March 29, 2006 that included an     <font color="blue">explanatory paragraph referring</font> to our recurring losses from <font color="blue">operations</font> and     <font color="blue">net capital deficiency</font> and expressing substantial doubt in our ability to     <font color="blue">continue as</font> a going concern without <font color="blue">additional</font> capital becoming available</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">continue as</font> a going concern is <font color="blue"><font color="blue">dependent</font> upon</font> our ability to     obtain  <font color="blue">additional</font>  equity or <font color="blue">debt financing</font>, attain further operating     efficiencies, reduce expenditures, and, ultimately, to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">financial statements</font> do not include any <font color="blue">adjustments</font> that might result from     the outcome of this <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>WE WILL NEED TO RAISE SUBSTANTIAL ADDITIONAL CAPITAL TO FUND OUR OPERATIONS,     AND OUR FAILURE TO OBTAIN FUNDING WHEN NEEDED MAY FORCE US TO DELAY, REDUCE     OR ELIMINATE OUR PRODUCT DEVELOPMENT PROGRAMS OR COLLABORATION EFFORTS        Our <font color="blue">operations</font> have consumed substantial amounts of <font color="blue">cash since inception</font></td>
    </tr>
    <tr>
      <td>We     expect to continue to spend substantial amounts to:         ·       complete the clinical <font color="blue">development</font> of our two lead <font color="blue">product <font color="blue">candidates</font></font>,     <font color="blue">Atiprimod </font>for the treatment of <font color="blue">multiple myeloma</font> and <font color="blue">advanced carcinoid</font>     cancer and L-<font color="blue">Annamycin </font>for the treatment of <font color="blue">acute leukemia</font>;         ·       continue the <font color="blue">development</font> of our other <font color="blue">product <font color="blue">candidates</font></font>;         ·       finance our general and <font color="blue">administrative expenses</font>;         ·       prepare <font color="blue">regulatory</font> approval <font color="blue">application</font>s and <font color="blue">seek approvals</font> for <font color="blue">Atiprimod </font>    and L-<font color="blue">Annamycin </font>and our other <font color="blue">product <font color="blue">candidates</font></font>;         ·       license or acquire <font color="blue">additional</font> <font color="blue">technologies</font>;         ·       launch and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>, if any such product     <font color="blue">candidates</font> receive <font color="blue">regulatory</font> approval; and         ·       develop and implement sales, marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>In 2005, our cash used in operating <font color="blue">activities</font> increased <font color="blue">significant</font>ly over     2004 and we expect that our cash used in operating <font color="blue"><font color="blue">activities</font> will increase</font>     <font color="blue">significant</font>ly for the <font color="blue">next <font color="blue">several years</font></font></td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31,     2005, we used approximately dlra8cmam700cmam000, or approximately dlra725cmam000 per month     in  operating  <font color="blue">activities</font>, as compared to approximately dlra4cmam700cmam000 and     dlra2cmam000cmam000  for  the  twelve  months ended <font color="blue">December </font>31, 2004 and 2003,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________           We will be required to raise <font color="blue">additional</font> capital within the next year to     complete  the <font color="blue">development</font> and <font color="blue">commercialization</font> of our <font color="blue">current product</font>     <font color="blue">candidates</font>  and  to  continue  to  fund <font color="blue">operations</font> at the <font color="blue">current cash</font>     <font color="blue">expenditure levels</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future funding <font color="blue">requirements</font> will depend on</font> many     factors, including, but not limited to:         ·       the rate of progress and cost of our <font color="blue">clinical trials</font> and other <font color="blue">development</font>     <font color="blue">activities</font>;         ·       any <font color="blue">future decisions</font> we may make about the scope and <font color="blue">prioritization</font> of the     programs we pursue;         ·       the costs of filing, prosecuting, defending and enforcing any patent claims     and other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>;         ·       the costs and timing of <font color="blue">regulatory</font> approval;         ·       the costs of establishing sales, marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font>;         ·       the effect of <font color="blue">competing technological</font> and market <font color="blue">development</font>s;         ·       the terms and timing of any <font color="blue">collaborative</font>, licensing and other <font color="blue"><font color="blue">arrangement</font>s</font>     that we <font color="blue">may establish</font>; and         ·       <font color="blue">general market <font color="blue">conditions</font></font> for <font color="blue">offerings from bio<font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>To date, our sources of cash have <font color="blue">been primarily</font> limited to the sale of our     <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>Net cash provided by financing <font color="blue">activities</font> for the twelve     months ended <font color="blue">December </font>31, 2005, 2004 and 2003 was approximately dlra4cmam800cmam000,     dlra6cmam100cmam000 and dlra3cmam800cmam000 <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that <font color="blue">additional</font>     <font color="blue">funding will</font> be <font color="blue">available on</font> acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>To the extent that     we raise <font color="blue">additional</font> funds by issuing <font color="blue">equity securities</font>, our <font color="blue">stockholders</font> may     experience <font color="blue">significant</font> dilution</td>
    </tr>
    <tr>
      <td>Any <font color="blue">debt financing</font>, if available, may     involve  <font color="blue">restrictive</font>  covenants that impact our ability to conduct our     business</td>
    </tr>
    <tr>
      <td>If we are unable to raise <font color="blue">additional</font> capital when required or on     acceptable  terms,  we  may have to <font color="blue">significant</font>ly delay, scale back or     <font color="blue">discontinue</font> the <font color="blue">development</font> and/or <font color="blue">commercialization</font> of one or more of our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We also may be required to:         ·       <font color="blue">seek collaborators</font> for our <font color="blue">product <font color="blue">candidates</font></font> at an <font color="blue">earlier stage than</font>     otherwise would be desirable and on terms that are less favorable than might     otherwise be available; and         ·       <font color="blue">relinquish license</font> or <font color="blue">otherwise dispose</font> of rights to <font color="blue">technologies</font>, product     <font color="blue">candidates</font> or products that we <font color="blue">would otherwise seek</font> to develop or     <font color="blue">commercialize</font> ourselves on unfavorable terms</td>
    </tr>
    <tr>
      <td>IF OUR AGREEMENTS WITH ANORMED INC OR THE UNIVERSITY OF TEXAS MD ANDERSON     CANCER CENTER TERMINATE, OUR BUSINESS WOULD BE ADVERSELY AFFECTED        Our business is <font color="blue"><font color="blue">dependent</font> on rights</font> we have <font color="blue">licensed from</font> <font color="blue">AnorMED Inc</font></td>
    </tr>
    <tr>
      <td>and     <font color="blue"><font color="blue">The University </font>of Texas MD Anderson Cancer Center</font></td>
    </tr>
    <tr>
      <td>Under the terms of the     AnorMED  license <font color="blue">agreement</font>, we are obligated to make a <font color="blue">maintenance fee</font>     payment of dlra200cmam000 on January 1 of <font color="blue">each year</font> for the term of the license     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Pursuant to the license <font color="blue">agreement</font>, failure to pay the maintenance     fee is a material breach of the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We do not anticipate failing to     pay the <font color="blue">maintenance fee</font>, however in the event we <font color="blue">cannot pay</font> the maintenance     fee, AnorMED <font color="blue">may terminate</font> the license <font color="blue">agreement</font> and we would not be able to     further develop and <font color="blue">commercialize</font> <font color="blue">Atiprimod </font><font color="blue">which would</font> have an adverse     effect on our business</td>
    </tr>
    <tr>
      <td>Under the terms of <font color="blue">The University </font>of Texas MD     Anderson Cancer Center license <font color="blue">agreement</font> for L-Annamycin, we are required to     make certain good <font color="blue">faith expenditures towards</font> the clinical <font color="blue">development</font> of at     <font color="blue">least one licensed product within</font> the <font color="blue">two year period</font> after March 2005</td>
    </tr>
    <tr>
      <td>In     addition, at any time after 5 years from August 12, 2004, <font color="blue">The University </font>of     <font color="blue">Texas MD Anderson Cancer Center </font>has the right to terminate the license if     we fail to provide evidence within 90 days of written notice that we have     <font color="blue">commercialize</font>d  or  we  are  actively  and  <font color="blue">effective</font>ly  attempting to     <font color="blue">commercialize</font> L-Annamycin</td>
    </tr>
    <tr>
      <td>If we fail to fulfill these <font color="blue">obligations</font> or other     material <font color="blue">obligations</font>, <font color="blue"><font color="blue">The University </font>of Texas MD Anderson Cancer Center</font>     license <font color="blue">agreement</font> may be terminated and our business would be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>CLINICAL TRIALS INVOLVE A LENGTHY AND EXPENSIVE PROCESS WITH AN UNCERTAIN     OUTCOME, AND RESULTS OF EARLIER STUDIES AND TRIALS MAY NOT BE PREDICTIVE OF     FUTURE TRIAL RESULTS        In order to receive <font color="blue">regulatory</font> approval for the <font color="blue">commercialization</font> of our     <font color="blue">product <font color="blue">candidates</font></font>, we must conduct, at our own expense, extensive clinical     trials to <font color="blue"><font color="blue">demonstrate</font> safety</font> and efficacy of these <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Failure can occur at any time during the clinical     <font color="blue">trial process</font></td>
    </tr>
    <tr>
      <td>The results of <font color="blue">preclinical studies</font> and early <font color="blue">clinical trials</font> of our product     <font color="blue">candidates</font> do not <font color="blue">necessarily predict</font> the results of later-stage clinical     trials</td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> in <font color="blue">later stages</font> of <font color="blue">clinical trials</font> may fail to     show  the desired safety and <font color="blue">efficacy traits despite</font> having progressed     <font color="blue">through initial clinical testing</font></td>
    </tr>
    <tr>
      <td>The data collected from <font color="blue">clinical trials</font> of     our <font color="blue">product <font color="blue">candidates</font></font> may not be sufficient to support the submission of a     <font color="blue">new drug <font color="blue">application</font></font> or to obtain <font color="blue">regulatory</font> approval in the <font color="blue"><font color="blue">United States</font>     </font>or elsewhere</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">uncertainties</font> <font color="blue">associated with</font> drug <font color="blue">development</font>     and <font color="blue">regulatory</font> approval, we cannot determine if or when we will have an     <font color="blue">approved product</font> for <font color="blue">commercialization</font> or achieve sales or profits</td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________           DELAYS IN CLINICAL TESTING COULD RESULT IN INCREASED COSTS TO US AND DELAY     OUR ABILITY TO GENERATE REVENUE        While to date there has been no delays in our <font color="blue">clinical trials</font>, <font color="blue">enrollment</font> in     our  <font color="blue">Atiprimod </font> Phase  I/IIa trial in <font color="blue">multiple myeloma</font> was <font color="blue">slower than</font>     anticipated  due  to limited <font color="blue">availability</font> of relapsed <font color="blue">multiple myeloma</font>     patients</td>
    </tr>
    <tr>
      <td>In the future, we may experience delays in clinical testing of our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We do not know whether planned <font color="blue">clinical trials</font> will     begin on time, will need to be redesigned or will be completed on schedule,     if  at  all</td>
    </tr>
    <tr>
      <td>Clinical trials can be delayed for a variety of reasons,     including delays in obtaining <font color="blue">regulatory</font> approval to commence a trial, in     reaching <font color="blue">agreement</font> on acceptable <font color="blue">clinical trial terms with prospective</font>     sites, in obtaining <font color="blue">institutional review board approval</font> to conduct a trial     at a <font color="blue">prospective site</font>, in <font color="blue">recruiting patients</font> to <font color="blue">participate</font> in a trial or     in obtaining <font color="blue">sufficient supplies</font> of <font color="blue">clinical trial materials</font></td>
    </tr>
    <tr>
      <td>Many factors     affect patient <font color="blue">enrollment</font>, including the size of the <font color="blue">patient population</font>, the     proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the     trial, competing <font color="blue">clinical trials</font> and <font color="blue">new drugs approved</font> for the <font color="blue">conditions</font>     we are <font color="blue">investigating</font></td>
    </tr>
    <tr>
      <td><font color="blue">Prescribing </font><font color="blue">physicians will also</font> have to decide to use     our <font color="blue">product <font color="blue">candidates</font></font> over existing drugs that have <font color="blue">established safety</font> and     efficacy  profiles</td>
    </tr>
    <tr>
      <td>Any delays in completing our <font color="blue">clinical trials</font> will     increase our costs, slow down our product <font color="blue">development</font> and <font color="blue">approval process</font>     and delay our ability to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>WE  MAY  BE  REQUIRED TO SUSPEND OR DISCONTINUE CLINICAL TRIALS DUE TO     UNEXPECTED SIDE EFFECTS OR OTHER SAFETY RISKS THAT COULD PRECLUDE APPROVAL     OF OUR PRODUCT CANDIDATES        Our <font color="blue">clinical trials</font> may be <font color="blue">suspended at</font> any time for a number of reasons</td>
    </tr>
    <tr>
      <td>For example, we <font color="blue">may voluntarily suspend</font> or terminate our <font color="blue">clinical trials</font> if     at  any  time we believe that they present an unacceptable risk to the     <font color="blue">clinical trial patients</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">regulatory</font> agencies may order the     temporary or <font color="blue">permanent dis<font color="blue">continuation</font></font> of our <font color="blue">clinical trials</font> at any time if     they believe that the <font color="blue">clinical trials</font> are not being conducted in <font color="blue">accordance</font>     with applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> or that they present an unacceptable     <font color="blue">safety risk</font> to the <font color="blue">clinical trial patients</font></td>
    </tr>
    <tr>
      <td><font color="blue">Administering </font>any <font color="blue">product <font color="blue">candidates</font></font> to humans may produce undesirable side     effects</td>
    </tr>
    <tr>
      <td>These side effects could interrupt, delay or halt <font color="blue">clinical trials</font>     of our <font color="blue">product <font color="blue">candidates</font></font> and could result in the FDA or other <font color="blue">regulatory</font>     <font color="blue">authorities</font>  denying  further  <font color="blue">development</font>  or approval of our product     <font color="blue">candidates</font> for any or all targeted <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>Ultimately, some or all of     our <font color="blue">product <font color="blue">candidates</font></font> may prove to be unsafe for human use</td>
    </tr>
    <tr>
      <td>Moreover, we     could  be subject to <font color="blue">significant</font> <font color="blue">liability</font> if any volunteer or patient     suffers,  or  appears to suffer, adverse health effects as a result of     <font color="blue">participating</font> in our <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>IF WE ARE UNABLE TO SATISFY REGULATORY REQUIREMENTS, WE MAY NOT BE ABLE TO     COMMERCIALIZE OUR PRODUCT CANDIDATES        We need FDA <font color="blue">approval prior</font> to marketing our <font color="blue">product <font color="blue">candidates</font></font> in the United     States of America</td>
    </tr>
    <tr>
      <td>If we fail to obtain FDA approval to market our product     <font color="blue">candidates</font>, we will be unable to sell our <font color="blue">product <font color="blue">candidates</font></font> in the United     States of America and we will not generate any revenue</td>
    </tr>
    <tr>
      <td>This <font color="blue">regulatory</font> review and <font color="blue">approval process</font>, which includes <font color="blue">evaluation</font> of     <font color="blue">preclinical studies</font> and <font color="blue">clinical trials</font> of a <font color="blue"><font color="blue">product candidate</font> as well as</font>     the <font color="blue">evaluation</font> of our <font color="blue"><font color="blue">manufacturing</font> process</font> and our <font color="blue">contract <font color="blue">manufacture</font>r</font>s &amp;apos      <font color="blue">facilities</font>, is lengthy, expensive and uncertain</td>
    </tr>
    <tr>
      <td>To receive approval, we     must,  among  other things, <font color="blue">demonstrate</font> with substantial <font color="blue">evidence from</font>     well-controlled <font color="blue">clinical trials</font> that the <font color="blue">product candidate</font> is both safe and     <font color="blue">effective</font> for <font color="blue">each indication</font> where approval is sought</td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of     these <font color="blue">requirements</font> typically takes <font color="blue">several years</font> and the time needed to     satisfy them may vary <font color="blue">substantially</font>, <font color="blue">based on</font> the type, <font color="blue">complexity</font> and     novelty of the <font color="blue"><font color="blue">pharmaceutical</font> product</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> if or when we might     submit for <font color="blue">regulatory</font> review any of our <font color="blue">product <font color="blue">candidates</font></font> currently under     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Any approvals we may obtain may not cover all of the clinical     <font color="blue">indications</font> for which we are <font color="blue">seeking approval</font></td>
    </tr>
    <tr>
      <td>Also, an approval might     contain <font color="blue">significant</font> <font color="blue">limitations</font> in the form of narrow <font color="blue">indications</font>, warnings,     <font color="blue">precautions</font>, or contra-<font color="blue">indications</font> <font color="blue">with respect</font> to <font color="blue">conditions</font> of use</td>
    </tr>
    <tr>
      <td>The FDA has substantial <font color="blue">discretion</font> in the <font color="blue">approval process</font> and may either     refuse  to file our <font color="blue">application</font> for <font color="blue">substantive review</font> or may form the     opinion after review of our data that our <font color="blue">application</font> is insufficient to     allow  approval of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>does not file or     approve our <font color="blue">application</font>, it may require that we conduct <font color="blue">additional</font> clinical,     preclinical or <font color="blue"><font color="blue">manufacturing</font> validation studies</font> and submit that data before     it <font color="blue">will reconsider</font> our <font color="blue">application</font></td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>on the extent of these or any     other studies, approval of any <font color="blue">application</font>s that we <font color="blue">submit may</font> be <font color="blue">delayed by</font>     <font color="blue">several years</font>, or may require us to expend more <font color="blue">resources than</font> we have     available</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that <font color="blue">additional</font> studies, if performed and     completed,  may  not  be  considered <font color="blue">sufficient by</font> the FDA to make our     <font color="blue">application</font>s approvable</td>
    </tr>
    <tr>
      <td>If any of these outcomes occur, we may be forced to     abandon  our  <font color="blue">application</font>s for approval, which might cause us to cease     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We will also be subject to a wide variety of <font color="blue">foreign <font color="blue">regulations</font> governing</font>     the <font color="blue">development</font>, <font color="blue">manufacture</font> and marketing of our products</td>
    </tr>
    <tr>
      <td>Whether or not     FDA approval has been obtained, approval of a product by the comparable     <font color="blue">regulatory</font> <font color="blue">authorities</font> of <font color="blue">foreign countries must still</font> be obtained prior to     <font color="blue">manufacturing</font> or marketing the product in those countries</td>
    </tr>
    <tr>
      <td>The approval     process  varies  <font color="blue">from country</font> to country and the time needed to secure     <font color="blue">approval may</font> be longer or <font color="blue">shorter than</font> that required for FDA approval</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that <font color="blue">clinical trials</font> conducted in <font color="blue">one country will</font> be     <font color="blue">accepted by</font> other countries or that approval in <font color="blue">one country will</font> result in     approval in any other country</td>
    </tr>
    <tr>
      <td>13       _________________________________________________________________           IF OUR PRODUCT CANDIDATES ARE UNABLE TO COMPETE EFFECTIVELY WITH MARKETED     CANCER DRUGS TARGETING SIMILAR INDICATIONS AS OUR PRODUCT CANDIDATES, OUR     COMMERCIAL OPPORTUNITY WILL BE REDUCED OR ELIMINATED        We  <font color="blue">face <font color="blue">competition</font> from established <font color="blue">pharmaceutical</font></font> and <font color="blue">bio<font color="blue">technology</font></font>     companies, as well as from academic institutions, <font color="blue">government</font> agencies and     private and <font color="blue">public research institutions</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have     <font color="blue">significant</font>ly greater financial resources and expertise in research and     <font color="blue">development</font>, <font color="blue">manufacturing</font>, preclinical testing, conducting <font color="blue">clinical trials</font>,     obtaining <font color="blue"><font color="blue">regulatory</font> approvals</font> and marketing <font color="blue">approved product</font>s than we do</td>
    </tr>
    <tr>
      <td><font color="blue">Smaller  </font>or  early-stage  companies  may  also prove to be <font color="blue">significant</font>     <font color="blue">competitors</font>, <font color="blue">particularly</font> through <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> with large,     established  companies</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial opportunity will</font> be reduced or     eliminated if our <font color="blue">competitors</font> develop and <font color="blue">commercialize</font> cancer drugs that     are safer, more <font color="blue">effective</font>, have fewer side effects or are <font color="blue">less expensive</font>     than  our  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">third parties</font> <font color="blue">compete with</font> us</font> in     recruiting and retaining <font color="blue">qualified scientific</font> and <font color="blue"><font color="blue">management</font> personnel</font>,     <font color="blue">establishing clinical <font color="blue">trial sites</font></font> and <font color="blue">patient registration</font> for clinical     trials,  as  well as in acquiring <font color="blue">technologies</font> and <font color="blue"><font color="blue">technology</font> licenses</font>     <font color="blue"><font color="blue">complement</font>ary</font> to our programs or <font color="blue">advantageous</font> to our business</td>
    </tr>
    <tr>
      <td>We expect that our ability to compete <font color="blue">effective</font>ly will depend upon our     ability to:         ·       <font color="blue">successfully</font> and rapidly complete <font color="blue">clinical trials</font> and submit for and obtain     all requisite <font color="blue"><font color="blue">regulatory</font> approvals</font> in a cost-<font color="blue">effective</font> manner;         ·       maintain a <font color="blue">proprietary position</font> for our products and <font color="blue"><font color="blue">manufacturing</font> process</font>es     and other related <font color="blue">product <font color="blue">technology</font></font>;         ·       attract and retain <font color="blue">key personnel</font>;         ·       develop <font color="blue"><font color="blue">relationships with</font> physicians prescribing</font> these products; and         ·       build an <font color="blue">adequate sales</font> and <font color="blue">marketing infrastructure</font> for our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Because we will be competing against <font color="blue">significant</font>ly larger companies with     <font color="blue">established track records</font>, we will have to <font color="blue">demonstrate</font> to physicians that,     <font color="blue">based on</font> experience, <font color="blue">clinical data</font>, side-effect profiles and other factors,     our products are preferable to <font color="blue">existing cancer drugs</font></td>
    </tr>
    <tr>
      <td>If we are unable to     compete <font color="blue">effective</font>ly in the <font color="blue">cancer drug market</font> and <font color="blue">different</font>iate our products     <font color="blue">from currently marketed cancer drugs</font>, we <font color="blue">may never generate meaningful</font>     revenue</td>
    </tr>
    <tr>
      <td><font color="blue">Numerous  </font><font color="blue">pharmaceutical</font>  and  <font color="blue">bio<font color="blue">technology</font></font>  companies have developed     <font color="blue">anthracycline drugs used</font> to treat <font color="blue"><font color="blue">acute leukemia</font>s</font> similar to our compound,     L-Annamycin</td>
    </tr>
    <tr>
      <td>These compounds include Adriamycin® and Ellence® which are     marketed  by  Pfizer  and  Cerubidine® which is <font color="blue">marketed by</font> Boehringer     Ingelheim</td>
    </tr>
    <tr>
      <td>These drugs have <font color="blue">been <font color="blue">approved by</font></font> the FDA and are currently being     marketed  as  opposed to L-<font color="blue">Annamycin </font>which is in clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Atiprimod, our <font color="blue">drug candidate</font> for relapsed <font color="blue">multiple myeloma</font>, works through a     <font color="blue">different</font> mechanism of <font color="blue">action than</font> Velcade which is currently <font color="blue">marketed by</font>     <font color="blue">Millenium Pharmaceuticals </font>and other drugs in <font color="blue">development</font>, such as Celgene     Corporation’s Revlimid</td>
    </tr>
    <tr>
      <td>WE CURRENTLY HAVE NO SALES AND MARKETING ORGANIZATION IF WE ARE UNABLE TO     ESTABLISH A DIRECT SALES FORCE IN THE UNITED STATES TO PROMOTE OUR PRODUCTS,     THE COMMERCIAL OPPORTUNITY FOR OUR PRODUCTS MAY BE DIMINISHED        We currently have no sales and <font color="blue">marketing organization</font></td>
    </tr>
    <tr>
      <td>If any of our product     <font color="blue">candidates</font>  are  <font color="blue">approved by</font> the FDA, we intend to market that product     directly to hospitals in the <font color="blue"><font color="blue">United States</font> of America </font>through our own sales     force</td>
    </tr>
    <tr>
      <td>We will incur <font color="blue">significant</font> <font color="blue">additional</font> expenses and commit <font color="blue">significant</font>     <font color="blue">additional</font> <font color="blue">management</font> resources to establish this <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>We may not be     able to establish these <font color="blue">capabilities</font> despite these <font color="blue">additional</font> expenditures</td>
    </tr>
    <tr>
      <td>We will also have to <font color="blue">compete with</font> other <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     companies to recruit, hire and <font color="blue">train sales</font> and <font color="blue">marketing personnel</font></td>
    </tr>
    <tr>
      <td>If we     elect to <font color="blue">rely on <font color="blue">third parties</font></font> to sell our <font color="blue">product <font color="blue">candidates</font></font> in the United     States, we may receive <font color="blue">less revenue than</font> if we sold our <font color="blue">products directly</font></td>
    </tr>
    <tr>
      <td>In addition, we may have little or <font color="blue">no <font color="blue">control over</font></font> the <font color="blue">sales efforts</font> of     those <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In the event we are unable to develop our own sales     force or <font color="blue">collaborate</font> with a <font color="blue">third party</font> to sell our <font color="blue">product <font color="blue">candidates</font></font>, we     may  not  be  able to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> <font color="blue">which would</font>     <font color="blue">negatively</font> impact our ability to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>WE MAY NEED OTHERS TO MARKET AND COMMERCIALIZE OUR PRODUCT CANDIDATES IN     INTERNATIONAL MARKETS        In the future, if <font color="blue">appropriate</font> <font color="blue"><font color="blue">regulatory</font> approvals</font> are obtained, we intend     to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>However,     we have not <font color="blue">decided how</font> to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> in those     markets</td>
    </tr>
    <tr>
      <td>We may decide to build our own <font color="blue">sales force</font> or sell our products     through  third  parties</td>
    </tr>
    <tr>
      <td>Currently, we do not have any plans to enter     <font color="blue">international</font>  markets</td>
    </tr>
    <tr>
      <td>If we decide to sell our <font color="blue">product <font color="blue">candidates</font></font> in     <font color="blue">international</font> markets through a <font color="blue">third party</font>, we may not be able to enter     into any marketing <font color="blue"><font color="blue">arrangement</font>s</font> on favorable terms or at all</td>
    </tr>
    <tr>
      <td>In addition,     these <font color="blue"><font color="blue">arrangement</font>s</font> could result in <font color="blue">lower levels</font> of income to us than if we     marketed our <font color="blue">product <font color="blue">candidates</font></font> entirely on our own</td>
    </tr>
    <tr>
      <td>If we are unable to     enter  into  a  marketing  <font color="blue">arrangement</font>  for  our <font color="blue">product <font color="blue">candidates</font></font> in     <font color="blue">international</font>  markets,  we  may  not  be able to develop an <font color="blue">effective</font>     <font color="blue">international</font> <font color="blue">sales force</font> to <font color="blue">successfully</font> <font color="blue">commercialize</font> those products in     <font color="blue">international</font> markets</td>
    </tr>
    <tr>
      <td>If we fail to enter into marketing <font color="blue"><font color="blue">arrangement</font>s</font> for     our products and are unable to develop an <font color="blue">effective</font> <font color="blue">international</font> sales     force, our ability to <font color="blue">generate revenue</font> would be limited</td>
    </tr>
    <tr>
      <td>A is our <font color="blue">sole supplier</font> of <font color="blue">Annamycin </font>(drug     substance that is the active component of the <font color="blue">final formulated</font> L-<font color="blue">Annamycin </font>    <font color="blue">drug product</font>)</td>
    </tr>
    <tr>
      <td>If our <font color="blue">relationship with</font> this <font color="blue">contract <font color="blue">manufacture</font>r</font>, or any     other <font color="blue">contract <font color="blue">manufacture</font>r</font> we might use, terminates or if any of their     <font color="blue">facilities</font> are damaged for any reason, including fire, flood, earthquake or     other similar event, we may be unable to obtain supply of Annamycin</td>
    </tr>
    <tr>
      <td>If any     of these events were to occur, we may need to find <font color="blue">alternative</font> <font color="blue"><font color="blue">manufacture</font>rs</font>     or <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The number of <font color="blue">contract <font color="blue">manufacture</font>r</font>s with the     expertise, required <font color="blue"><font color="blue">regulatory</font> approvals</font> and <font color="blue">facilities</font> to <font color="blue">manufacture</font>     <font color="blue">Annamycin </font>on a <font color="blue">commercial scale</font> is extremely limited, and it would take a     <font color="blue">significant</font> amount of time to arrange for <font color="blue">alternative</font> <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>If we     need to change to other commercial <font color="blue"><font color="blue">manufacture</font>rs</font>, the FDA and comparable     foreign  <font color="blue">regulators</font>  must  approve these <font color="blue"><font color="blue">manufacture</font>rs</font>’ <font color="blue">facilities</font> and     processes prior to our use, <font color="blue">which would</font> require new testing and compliance     <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>In addition, we may not have the <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>,     or may have to share <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font>, to any <font color="blue">improvements</font> in     the current <font color="blue"><font color="blue">manufacturing</font> process</font>es or any new <font color="blue"><font color="blue">manufacturing</font> process</font>es for     Annamycin</td>
    </tr>
    <tr>
      <td>Any of these factors could cause us to delay or suspend clinical     trials, <font color="blue">regulatory</font> <font color="blue">submissions</font>, required approvals or <font color="blue">commercialization</font> of     L-Annamycin, <font color="blue">entail higher costs</font>, and could result in our being unable to     <font color="blue">commercialize</font>  L-<font color="blue">Annamycin </font> <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Furthermore, if our contract     <font color="blue"><font color="blue">manufacture</font>rs</font> fail to deliver the required <font color="blue">commercial quantities</font> of bulk     drug substance or finished <font color="blue">product on</font> a <font color="blue">timely basis</font> and <font color="blue">at commercially</font>     reasonable  prices, and we were unable to find one or more <font color="blue">replacement</font>     <font color="blue"><font color="blue">manufacture</font>rs</font> capable of <font color="blue">production at</font> a <font color="blue"><font color="blue">substantially</font> equivalent cost</font>, in     <font color="blue"><font color="blue">substantially</font> equivalent volumes</font> and quality, and on a <font color="blue">timely basis</font>, we     would likely be unable to meet demand for L-<font color="blue">Annamycin </font>and we would lose     potential revenue</td>
    </tr>
    <tr>
      <td>IF THE FDA DOES NOT APPROVE OUR CONTRACT MANUFACTURERS &amp;apos  FACILITIES, WE MAY     BE UNABLE TO DEVELOP OR COMMERCIALIZE OUR PRODUCT CANDIDATES        We rely on third-party <font color="blue">contract <font color="blue">manufacture</font>r</font>s to <font color="blue">manufacture</font> our product     <font color="blue">candidates</font>, and currently have no plans to develop our own <font color="blue">manufacturing</font>     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">facilities</font> used by our <font color="blue">contract <font color="blue">manufacture</font>r</font>s to <font color="blue">manufacture</font>     our <font color="blue">product <font color="blue">candidates</font></font> must be <font color="blue">approved by</font> the FDA <font color="blue">If the FDA </font>does not     approve these <font color="blue">facilities</font> for the <font color="blue">manufacture</font> of our product, we may need to     fund  <font color="blue">additional</font>  <font color="blue">modifications</font>  to our <font color="blue"><font color="blue">manufacturing</font> process</font>, conduct     <font color="blue">additional</font> validation studies, or find <font color="blue">alternative</font> <font color="blue">manufacturing</font> <font color="blue">facilities</font>,     any of <font color="blue">which would</font> result in <font color="blue">significant</font> cost to <font color="blue">us as well as</font> a delay of up     to <font color="blue">several years</font> in obtaining approval for and <font color="blue">manufacturing</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">contract <font color="blue">manufacture</font>r</font>s will be subject to     <font color="blue">ongoing periodic unannounced inspection by</font> the FDA and <font color="blue">corresponding</font> state     agencies for <font color="blue">compliance with</font> good <font color="blue">manufacturing</font> practices <font color="blue">regulations</font>, or     cGMPs, and similar foreign standards</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> cover all aspects of     the <font color="blue">manufacturing</font>, testing, quality control and record keeping relating to     our  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We  do  not  have <font color="blue">control over</font> our contract     <font color="blue"><font color="blue">manufacture</font>rs</font> &amp;apos  <font color="blue">compliance with</font> these <font color="blue">regulations</font> and standards</td>
    </tr>
    <tr>
      <td>Failure by     our <font color="blue">contract <font color="blue">manufacture</font>r</font>s to <font color="blue">comply with</font> applicable <font color="blue">regulations</font> could     result in sanctions being <font color="blue">imposed on us</font>, including fines, injunctions, civil     penalties, failure of the <font color="blue">government</font> to <font color="blue">grant market approval</font> of drugs,     delays, suspension or <font color="blue">withdrawals</font> of approvals, operating <font color="blue">restrictions</font> and     <font color="blue"><font color="blue">criminal prosecution</font>s</font>, any of which could <font color="blue">significant</font>ly and <font color="blue">adversely</font> affect     our  business</td>
    </tr>
    <tr>
      <td>In  addition,  we  have  no  <font color="blue">control over</font> our contract     <font color="blue"><font color="blue">manufacture</font>rs</font> &amp;apos   ability  to maintain adequate quality control, quality     assurance and <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>Failure by our <font color="blue">contract <font color="blue">manufacture</font>r</font>s to     <font color="blue">comply with</font> or maintain any of these standards could <font color="blue">adversely</font> affect the     <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> and our business</td>
    </tr>
    <tr>
      <td>IF PRODUCT LIABILITY LAWSUITS ARE SUCCESSFULLY BROUGHT AGAINST US, WE MAY     INCUR SUBSTANTIAL LIABILITIES AND MAY BE REQUIRED TO LIMIT COMMERCIALIZATION     OF OUR PRODUCT CANDIDATES        We  face an <font color="blue">inherent risk</font> of <font color="blue"><font color="blue">product <font color="blue">liability</font></font> lawsuits</font> related to the     testing of our <font color="blue">product <font color="blue">candidates</font></font>, and will face an <font color="blue">even greater risk</font> if we     sell our <font color="blue">product <font color="blue">candidates</font></font> commercially</td>
    </tr>
    <tr>
      <td>Currently, we are not aware of any     anticipated <font color="blue">product <font color="blue">liability</font></font> claims <font color="blue">with respect</font> to our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In the future, an individual may bring a <font color="blue">liability</font> claim against us if one     of our <font color="blue">product <font color="blue">candidates</font></font> causes, or merely appears to have caused, an     injury</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font> defend ourselves against the product     <font color="blue">liability</font> claim, we may incur substantial <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of merit     or eventual outcome, <font color="blue">liability</font> claims may result in:         ·       decreased demand for our <font color="blue">product <font color="blue">candidates</font></font>;         ·       injury to our reputation;         ·       withdrawal of clinical trial <font color="blue">participants</font>;         ·       costs of related <font color="blue">litigation</font>;         ·       substantial monetary awards to patients;         ·       product recalls;         ·       loss of revenue; and         ·       the <font color="blue">inability</font> to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We  have  clinical  trial <font color="blue">liability</font> insurance with a dlra3cmam000cmam000 annual     <font color="blue">aggregate limit</font> for up to 40 patients <font color="blue">participating</font> at the same time in our     <font color="blue">Atiprimod </font>and L-<font color="blue">Annamycin </font><font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We intend to expand our insurance     coverage to include the sale of <font color="blue">commercial products</font> if <font color="blue">marketing approval</font> is     obtained for our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">current <font color="blue">insurance coverage</font> may</font>     prove insufficient to cover any <font color="blue">liability</font> claims <font color="blue">brought against us</font></td>
    </tr>
    <tr>
      <td>In     addition, because of the <font color="blue">increasing costs</font> of <font color="blue">insurance coverage</font>, we may not     be  able to maintain <font color="blue">insurance coverage</font> at a <font color="blue">reasonable cost</font> or obtain     <font color="blue">insurance coverage</font> that will be adequate to satisfy any <font color="blue">liability</font> that may     arise</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________           EVEN IF WE RECEIVE REGULATORY APPROVAL FOR OUR PRODUCT CANDIDATES, WE WILL     BE SUBJECT TO ONGOING SIGNIFICANT REGULATORY OBLIGATIONS AND OVERSIGHT        If we receive <font color="blue">regulatory</font> approval to sell our <font color="blue">product <font color="blue">candidates</font></font>, the FDA     and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> may, <font color="blue">nevertheless</font>, impose <font color="blue">significant</font>     <font color="blue">restrictions</font> on the indicated uses or marketing of such products, or impose     ongoing <font color="blue">requirements</font> for post-approval studies</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>any <font color="blue">regulatory</font>     approval  of  our <font color="blue">product <font color="blue">candidates</font></font>, we will be subject to continuing     <font color="blue">regulatory</font>  <font color="blue">obligations</font>,  such  as  safety reporting <font color="blue">requirements</font>, and     <font color="blue">additional</font> post-marketing <font color="blue">obligations</font>, including <font color="blue">regulatory</font> oversight of the     promotion and marketing of our products</td>
    </tr>
    <tr>
      <td>If we <font color="blue">become aware</font> of <font color="blue">previously</font>     <font color="blue">unknown problems with</font> any of our <font color="blue">product <font color="blue">candidates</font></font> here or overseas or our     contract  <font color="blue"><font color="blue">manufacture</font>rs</font> &amp;apos   <font color="blue">facilities</font>,  a  <font color="blue">regulatory</font> agency may impose     <font color="blue">restrictions</font> on our products, our <font color="blue">contract <font color="blue">manufacture</font>r</font>s or on us, including     requiring  us to <font color="blue">reformulate</font> our products, conduct <font color="blue">additional</font> clinical     trials, make changes in the labeling of our products, implement changes to     or obtain re-approvals of our <font color="blue">contract <font color="blue">manufacture</font>r</font>s &amp;apos  <font color="blue">facilities</font> or withdraw     the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>In addition, we may experience a <font color="blue">significant</font>     drop  in  the  sales  of  the <font color="blue">affected products</font>, our reputation in the     <font color="blue">marketplace may suffer</font> and we may become the target of lawsuits, including     class  action  suits</td>
    </tr>
    <tr>
      <td>Moreover,  if we fail to <font color="blue">comply with</font> applicable     <font color="blue">regulatory</font>  <font color="blue">requirements</font>,  we  may  be subject to fines, suspension or     withdrawal of <font color="blue"><font color="blue">regulatory</font> approvals</font>, product recalls, seizure of products,     operating <font color="blue">restrictions</font> and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Any of these events could     harm  or prevent sales of the <font color="blue">affected products</font> or <font color="blue">could <font color="blue">substantially</font></font>     increase the costs and expenses of <font color="blue">commercializing</font> and marketing these     products</td>
    </tr>
    <tr>
      <td>WE RELY ON THIRD PARTIES TO CONDUCT OUR CLINICAL TRIALS IF THESE THIRD     PARTIES DO NOT SUCCESSFULLY CARRY OUT THEIR CONTRACTUAL DUTIES OR MEET     EXPECTED DEADLINES, WE MAY NOT BE ABLE TO SEEK OR OBTAIN REGULATORY APPROVAL     FOR OR COMMERCIALIZE OUR PRODUCT CANDIDATES        We have <font color="blue">agreement</font>s with third-party contract research organizations, or     CROs, to provide monitors and to <font color="blue">manage data</font> for our <font color="blue">clinical programs</font></td>
    </tr>
    <tr>
      <td>We     and our CROs are required to <font color="blue">comply with</font> current Good Clinical Practices, or     GCPs, <font color="blue">regulations</font> and <font color="blue">guidelines enforced by</font> the FDA for all of our products     in clinical <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The FDA enforces GCPs through periodic <font color="blue">inspections</font>     of trial sponsors, principal investigators and <font color="blue">trial sites</font></td>
    </tr>
    <tr>
      <td>In the future,     if we or our CROs fail to <font color="blue">comply with</font> applicable GCPs, the <font color="blue">clinical data</font>     generated in our <font color="blue">clinical trials</font> may be deemed unreliable <font color="blue">and the FDA </font>may     require  us to perform <font color="blue">additional</font> <font color="blue">clinical trials</font> before approving our     marketing <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that, <font color="blue">upon inspection</font>, the FDA     will determine that any of our <font color="blue">clinical trials</font> for products in clinical     <font color="blue">development</font> <font color="blue">comply with</font> GCPs</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">clinical trials</font> must be     <font color="blue">conducted with product</font> produced under cGMP <font color="blue">regulations</font>, and will require a     large number of <font color="blue">test subjects</font></td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> these <font color="blue">regulations</font>     may require us to repeat <font color="blue">clinical trials</font>, <font color="blue">which would</font> delay the <font color="blue">regulatory</font>     <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">relationships with</font> these third-party CROs terminate, we may     not be able to enter into <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">alternative</font> CROs</td>
    </tr>
    <tr>
      <td>If CROs do not     <font color="blue">successfully</font> carry out their <font color="blue">contractual duties</font> or <font color="blue">obligations</font> or meet     expected  <font color="blue">deadlines</font>, if they need to be replaced, or if the quality or     accuracy of the <font color="blue">clinical data</font> they obtain is <font color="blue">compromised due</font> to the failure     to adhere to our clinical protocols, <font color="blue">regulatory</font> <font color="blue">requirements</font> or for other     reasons, our <font color="blue">clinical trials</font> may be extended, delayed or terminated, and we     may  not  be  able  to  obtain <font color="blue">regulatory</font> approval for or <font color="blue">successfully</font>     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>As a result, our financial results and     the commercial prospects for our <font color="blue">product <font color="blue">candidates</font></font> would be harmed, our     costs could increase, and our ability to <font color="blue">generate revenue</font> could be delayed</td>
    </tr>
    <tr>
      <td>IF  WE  FAIL  TO ATTRACT AND KEEP SENIOR MANAGEMENT AND KEY SCIENTIFIC     PERSONNEL, WE MAY BE UNABLE TO SUCCESSFULLY DEVELOP OUR PRODUCT CANDIDATES,     CONDUCT OUR CLINICAL TRIALS AND COMMERCIALIZE OUR PRODUCT CANDIDATES        Our <font color="blue">success depends</font> in part on our <font color="blue">continued ability</font> to attract, retain and     motivate highly qualified <font color="blue">management</font>, clinical and <font color="blue">scientific personnel</font> and     on our ability to develop and maintain important <font color="blue">relationships with</font> leading     academic institutions, clinicians and <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">highly <font color="blue">dependent</font></font>     upon our <font color="blue">senior <font color="blue">management</font></font> and scientific staff, <font color="blue">particularly</font> Gary S Jacob,     our Chief Executive Officer and Donald Picker, our Executive Vice President,     R&amp;D The loss of services of Drs</td>
    </tr>
    <tr>
      <td>Jacob, Picker or one or more of our other     members  of  senior  <font color="blue">management</font>  could delay or prevent the successful     <font color="blue">completion</font> of our planned <font color="blue">clinical trials</font> or the <font color="blue">commercialization</font> of our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">competition</font>  for  qualified  personnel  in  the <font color="blue">bio<font color="blue">technology</font></font> and     <font color="blue">pharmaceutical</font>s field is intense</td>
    </tr>
    <tr>
      <td>We will need to hire <font color="blue">additional</font> personnel     as we expand our clinical <font color="blue">development</font> and commercial <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We may not     be able to attract and retain <font color="blue">quality personnel on</font> acceptable <font color="blue">terms given</font>     the <font color="blue">competition</font> for such personnel among <font color="blue">bio<font color="blue">technology</font></font>, <font color="blue">pharmaceutical</font> and     other companies</td>
    </tr>
    <tr>
      <td>We do not carry  &amp;quote key person &amp;quote  <font color="blue">insurance covering</font> any members     of our <font color="blue">senior <font color="blue">management</font></font></td>
    </tr>
    <tr>
      <td>IF WE FAIL TO ACQUIRE AND DEVELOP OTHER PRODUCTS OR PRODUCT CANDIDATES, WE     MAY BE UNABLE TO GROW OUR BUSINESS        To date, we have in-licensed or acquired the rights to each of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>As part of our <font color="blue">growth strategy</font>, in addition to developing our     current <font color="blue">product <font color="blue">candidates</font></font>, we intend to license or acquire <font color="blue">additional</font>     products and <font color="blue">product <font color="blue">candidates</font></font> for <font color="blue">development</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Because we have limited internal research <font color="blue">capabilities</font>, we are <font color="blue">dependent</font>     upon <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies and other <font color="blue">researchers</font> to     sell or <font color="blue">license products</font> to us</td>
    </tr>
    <tr>
      <td>The success of this <font color="blue">strategy depends upon</font>     our ability to identify, select and acquire the right <font color="blue"><font color="blue">pharmaceutical</font> product</font>     <font color="blue">candidates</font> and products</td>
    </tr>
    <tr>
      <td>We currently do not have any <font color="blue">intentions</font> to acquire     another company</td>
    </tr>
    <tr>
      <td>Any  product  candidate  we  license or acquire may require <font color="blue">additional</font>     <font color="blue">development</font> efforts prior to <font color="blue">commercial sale</font>, including extensive clinical     testing  and  approval  by  the  FDA and applicable foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>All <font color="blue">product <font color="blue">candidates</font></font> are prone to the risks of failure     inherent in <font color="blue"><font color="blue">pharmaceutical</font> product</font> <font color="blue">development</font>, including the <font color="blue">possibility</font>     that the <font color="blue">product candidate</font> will not be shown to be <font color="blue">sufficiently safe</font> and     <font color="blue">effective</font> for approval by <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>In addition, we cannot     assure you that any products that we license or acquire that are approved     will be <font color="blue">manufacture</font>d or produced economically, <font color="blue">successfully</font> <font color="blue">commercialize</font>d     or <font color="blue">widely accepted</font> in the marketplace</td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________           Proposing, <font color="blue">negotiating</font> and <font color="blue">implementing</font> an <font color="blue">economically viable product</font>     <font color="blue">acquisition</font> or license is a lengthy and <font color="blue">complex process</font></td>
    </tr>
    <tr>
      <td>Other companies,     including those with <font color="blue">substantially</font> greater financial, marketing and sales     resources, may <font color="blue">compete with</font> us for the <font color="blue">acquisition</font> or license of product     <font color="blue">candidates</font> and <font color="blue">approved product</font>s</td>
    </tr>
    <tr>
      <td>We may not be able to acquire or license     the rights to <font color="blue">additional</font> <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">approved product</font>s on terms     that we find acceptable, or at all</td>
    </tr>
    <tr>
      <td>WE MAY UNDERTAKE ACQUISITIONS IN THE FUTURE, AND ANY DIFFICULTIES FROM     INTEGRATING  THESE  ACQUISITIONS COULD DAMAGE OUR ABILITY TO ATTAIN OR     MAINTAIN PROFITABILITY        We may acquire <font color="blue">additional</font> businesses, products or <font color="blue">product <font color="blue">candidates</font></font> that     <font color="blue">complement</font> or augment our existing business</td>
    </tr>
    <tr>
      <td><font color="blue">Integrating </font>any newly acquired     business or product could be expensive and time-consuming</td>
    </tr>
    <tr>
      <td>We may not be     able to integrate any acquired business or product <font color="blue">successfully</font> or operate     any acquired business profitably</td>
    </tr>
    <tr>
      <td>Moreover, we many need to raise <font color="blue">additional</font>     funds  through  public  or  private  debt  or <font color="blue">equity financing</font> to make     <font color="blue">acquisition</font>s,  which  may  result  in dilution to <font color="blue">stockholders</font> and the     incurrence of <font color="blue">indebtedness</font> that may include <font color="blue">restrictive</font> covenants</td>
    </tr>
    <tr>
      <td>To continue our <font color="blue">clinical trials</font> and <font color="blue">commercialize</font> our     <font color="blue">product <font color="blue">candidates</font></font>, we will need to expand our <font color="blue">employee base</font> for managerial,     operational,  financial and other resources</td>
    </tr>
    <tr>
      <td>Future <font color="blue">growth will impose</font>     <font color="blue">significant</font> added responsibilities on members of <font color="blue">management</font>, including the     need to identify, recruit, maintain and integrate <font color="blue">additional</font> employees</td>
    </tr>
    <tr>
      <td><font color="blue">Over     </font>the next 12 months depending on the progress of our planned <font color="blue">clinical trials</font>,     we plan to add <font color="blue">additional</font> employees to assist us with our <font color="blue">clinical programs</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">future financial performance</font> and our ability to <font color="blue">commercialize</font> our     <font color="blue">product <font color="blue">candidates</font></font> and to compete <font color="blue">effective</font>ly will depend, in part, on our     ability to manage any future growth <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>To that end, we must be     able to:         ·       manage our <font color="blue">development</font> efforts <font color="blue">effective</font>ly;         ·       manage our <font color="blue">clinical trials</font> <font color="blue">effective</font>ly;         ·       integrate <font color="blue">additional</font> <font color="blue">management</font>, administrative, <font color="blue">manufacturing</font> and sales and     <font color="blue">marketing personnel</font>;         ·       maintain sufficient administrative, accounting and <font color="blue">management</font> information     systems and controls; and         ·       hire and train <font color="blue">additional</font> <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We may not be able to accomplish these tasks, and our failure to accomplish     any of <font color="blue">them could harm</font> our financial results</td>
    </tr>
    <tr>
      <td>REIMBURSEMENT MAY NOT BE AVAILABLE FOR OUR PRODUCT CANDIDATES, WHICH COULD     DIMINISH OUR SALES        Market  <font color="blue">acceptance</font>  and  sales of our <font color="blue">product <font color="blue">candidates</font></font> may depend on     <font color="blue"><font color="blue">reimbursement</font> policies</font> and <font color="blue">health care reform measures</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">levels at which</font>     <font color="blue">government</font>  <font color="blue">authorities</font> and third-party payors, such as private health     insurers and health <font color="blue">maintenance organizations</font>, reimburse patients for the     price  they  pay  for our products <font color="blue">could affect</font> whether we are able to     <font color="blue">commercialize</font> these products</td>
    </tr>
    <tr>
      <td>We cannot be sure that <font color="blue"><font color="blue">reimbursement</font> will</font> be     available  for  any  of  these  products</td>
    </tr>
    <tr>
      <td>Also, we cannot be sure that     <font color="blue"><font color="blue">reimbursement</font> amounts will</font> not reduce the demand for, or the price of, our     products</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">commenced efforts</font> to have our <font color="blue">product <font color="blue">candidates</font></font>     reimbursed by <font color="blue">government</font> or <font color="blue">third party</font> payors</td>
    </tr>
    <tr>
      <td>If <font color="blue">reimbursement</font> is not     available or is <font color="blue">available on</font>ly to limited levels, we may not be able to     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, officials have made <font color="blue">numerous proposals</font> to change the health     <font color="blue">care system</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>These proposals include measures that     <font color="blue">would limit</font> or <font color="blue">prohibit payments</font> for <font color="blue">certain medical treatments</font> or subject     the pricing of drugs to <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>In addition, in many foreign     countries, <font color="blue">particularly</font> the countries of the European Union, the pricing of     <font color="blue">prescription</font> drugs is subject to <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td>If our products are or     become subject to <font color="blue">government</font> regulation that limits or <font color="blue">prohibits payment</font> for     our products, or that subject the price of our products to <font color="blue">government</font>al     control, we may not be able to <font color="blue">generate revenue</font>, attain <font color="blue">profitability</font> or     <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>As a result of <font color="blue">legislative</font> proposals and the <font color="blue">trend towards managed health</font>     care in the <font color="blue">United States</font>, third-party payers are <font color="blue">increasingly attempting</font> to     contain  health  <font color="blue">care costs by limiting both coverage</font> and the level of     <font color="blue">reimbursement</font> of new drugs</td>
    </tr>
    <tr>
      <td>They <font color="blue">may also refuse</font> to provide any coverage of     uses of <font color="blue">approved product</font>s for medical <font color="blue">indications</font> other than those for which     the FDA has <font color="blue">granted market approvals</font></td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">significant</font> <font color="blue">uncertainty</font>     exists as to whether and how much third-party payers will reimburse patients     for their use of newly-approved drugs, which in turn will put pressure on     the pricing of drugs</td>
    </tr>
    <tr>
      <td>LEGISLATIVE OR REGULATORY REFORM OF THE HEALTHCARE SYSTEM MAY AFFECT OUR     ABILITY TO SELL OUR PRODUCTS PROFITABLY        In both the <font color="blue">United States</font> and certain foreign <font color="blue">jurisdictions</font>, there have been     a number of <font color="blue">legislative</font> and <font color="blue">regulatory</font> proposals to change the healthcare     system in ways that could impact upon our ability to sell our products     profitably</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, new legislation has <font color="blue">been proposed</font> in the United     States at the federal and state levels that would effect major changes in     the health<font color="blue">care system</font>, either nationally or at the state level</td>
    </tr>
    <tr>
      <td>These  proposals have included <font color="blue">prescription</font> drug benefit proposals for     <font color="blue">Medicare  </font><font color="blue">beneficiaries introduced</font> in Congress</td>
    </tr>
    <tr>
      <td><font color="blue">Legislation </font>creating a     <font color="blue">prescription</font>  drug  benefit  and  making  certain  changes in <font color="blue">Medicaid     </font><font color="blue">reimbursement</font>  has <font color="blue">recently been enacted by</font> <font color="blue">Congress </font>and signed by the     President</td>
    </tr>
    <tr>
      <td>Given this legislationapstas recent enactment, it is <font color="blue">still too early</font>     to determine its <font color="blue">impact on</font> the <font color="blue">pharmaceutical</font> industry and our business</td>
    </tr>
    <tr>
      <td>The potential for adoption     of these <font color="blue">proposals affects</font> or will affect our ability to <font color="blue">raise capital</font>,     obtain  <font color="blue">additional</font> collaborators and market our products</td>
    </tr>
    <tr>
      <td>We expect to     experience <font color="blue">pricing pressures</font> in <font color="blue">connection with</font> the sale of our <font color="blue">products due</font>     to the <font color="blue">trend toward managed health care</font>, the <font color="blue">increasing influence</font> of health     <font color="blue">maintenance organizations</font> and <font color="blue">additional</font> <font color="blue">legislative</font> proposals</td>
    </tr>
    <tr>
      <td>Our results     of <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue">adversely</font> affected by future healthcare reforms</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________           RISKS RELATED TO OUR INTELLECTUAL PROPERTY       IT IS DIFFICULT AND COSTLY TO PROTECT OUR PROPRIETARY RIGHTS, AND WE MAY NOT     BE ABLE TO ENSURE THEIR PROTECTION        Our <font color="blue">commercial success will depend</font> in part on obtaining and maintaining     <font color="blue">patent protection</font> and <font color="blue">trade secret protection</font> of our <font color="blue">product <font color="blue">candidates</font></font>, and     the <font color="blue">methods used</font> to <font color="blue">manufacture</font> them, as well as <font color="blue">successfully</font> defending     these  patents against third-party challenges</td>
    </tr>
    <tr>
      <td>We will only be able to     protect our <font color="blue">product <font color="blue">candidates</font></font> from unauthorized making, using, selling,     offering to sell or importation by <font color="blue">third parties</font> to the extent that we have     <font color="blue">rights under valid</font> and <font color="blue">enforceable patents</font> or <font color="blue">trade secrets</font> that cover these     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>20, 2006, we own and/or have <font color="blue">licensed rights</font> to 15 issued United     States  patents  and  7  United  States  patent  <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>We may     file <font color="blue">additional</font> patent <font color="blue">application</font>s and <font color="blue">extensions</font></td>
    </tr>
    <tr>
      <td>Our issued <font color="blue"><font color="blue">United States</font>     </font>patents  we  own  and  <font color="blue">license primarily</font> are <font color="blue">composition</font> of matter and     <font color="blue">formulation patents</font> related to <font color="blue">Atiprimod </font>and L-Annamycin</td>
    </tr>
    <tr>
      <td>Our <font color="blue">composition</font> of     matter  patents for L-<font color="blue">Annamycin </font>and <font color="blue">Atiprimod </font>expire in 2017 and 2016,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Our  formulation  patents for L-<font color="blue">Annamycin </font>and <font color="blue">Atiprimod </font>    dimaleate (preferred salt form) both expire in 2016</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies can be     <font color="blue">highly uncertain</font> and <font color="blue">involve complex legal</font> and factual questions for which     <font color="blue">important legal principles remain unresolved</font></td>
    </tr>
    <tr>
      <td>No <font color="blue">consistent policy</font> regarding     the breadth of claims allowed in <font color="blue">bio<font color="blue">technology</font></font> patents has emerged to date     in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font></font> patent situation outside the United     States is even more uncertain</td>
    </tr>
    <tr>
      <td>Changes in either the <font color="blue">patent laws</font> or in     <font color="blue"><font color="blue">interpretation</font>s</font> of <font color="blue">patent laws</font> in the <font color="blue">United States</font> and other <font color="blue">countries may</font>     diminish the value of our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>Accordingly, we cannot     predict  the  breadth of claims that may be allowed or enforced in our     <font color="blue">licensed patents</font> or in third-party patents</td>
    </tr>
    <tr>
      <td>The degree of <font color="blue">future protection</font> for our <font color="blue">proprietary rights</font> is uncertain     because legal means <font color="blue">afford only</font> limited protection and may not <font color="blue">adequately</font>     protect our rights or <font color="blue">permit us</font> to gain or keep our <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>For example:         ·       <font color="blue">others may</font> be able to make compounds that are <font color="blue">competitive</font> with our product     <font color="blue">candidates</font> but that are not <font color="blue">covered by</font> the claims of our <font color="blue">licensed patents</font>,     or for which we are not <font color="blue">licensed under</font> our license <font color="blue">agreement</font>s;         ·       we or our <font color="blue"><font color="blue">licensors</font> might</font> not have been the first to make the <font color="blue">inventions</font>     <font color="blue">covered by</font> our pending patent <font color="blue">application</font> or the pending patent <font color="blue">application</font>s     and <font color="blue">issued patents</font> of our <font color="blue">licensors</font>;         ·       we or our <font color="blue"><font color="blue">licensors</font> might</font> not have been the first to <font color="blue">file patent</font>     <font color="blue">application</font>s for these <font color="blue">inventions</font>;         ·       <font color="blue">others may</font> in<font color="blue">dependent</font>ly develop similar or <font color="blue">alternative</font> <font color="blue">technologies</font> or     duplicate any of our <font color="blue">technologies</font>;         ·       it is possible that our pending patent <font color="blue">application</font> or one or more of the     pending patent <font color="blue">application</font>s of our <font color="blue"><font color="blue">licensors</font> will</font> not result in issued     patents;         ·       the <font color="blue">issued patents</font> of our <font color="blue"><font color="blue">licensors</font> may</font> not <font color="blue">provide us with</font> any <font color="blue">competitive</font>     <font color="blue">advantages</font>, or may be held invalid or <font color="blue">unenforceable as</font> a result of legal     challenges by <font color="blue">third parties</font>;         ·       we may not develop <font color="blue">additional</font> proprietary <font color="blue">technologies</font> that are patentable;     or         ·       the patents of <font color="blue">others may</font> have an adverse effect on our business</td>
    </tr>
    <tr>
      <td>We also may rely on <font color="blue">trade secrets</font> to protect our <font color="blue">technology</font>, <font color="blue">especially</font>     where we do not believe <font color="blue">patent protection</font> is <font color="blue">appropriate</font> or obtainable</td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font> are <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>While we use reasonable     efforts  to  protect  our  trade  secrets, our employees, consultants,     <font color="blue">contractors</font>,  outside  <font color="blue">scientific collaborators</font> and other <font color="blue">advisors may</font>     <font color="blue">unintentionally</font>  or willfully disclose our information to <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Enforcing </font>a claim that a <font color="blue">third party</font> illegally obtained and is using our     trade  secrets  is  expensive  and  time consuming, and the outcome is     unpredictable</td>
    </tr>
    <tr>
      <td>In addition, courts outside the <font color="blue">United States</font> are sometimes     less  willing  to protect <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Moreover, our <font color="blue">competitors</font> may     in<font color="blue">dependent</font>ly develop equivalent knowledge, methods and know-how</td>
    </tr>
    <tr>
      <td>WE  MAY  INCUR  SUBSTANTIAL  COSTS  AS A RESULT OF LITIGATION OR OTHER     PROCEEDINGS RELATING TO PATENT AND OTHER INTELLECTUAL PROPERTY RIGHTS AND WE     MAY BE UNABLE TO PROTECT OUR RIGHTS TO, OR USE, OUR TECHNOLOGY        If we choose to go to court to stop someone <font color="blue">else from using</font> the <font color="blue">inventions</font>     claimed in our <font color="blue">licensed patents</font>, that individual or company has the right to     ask the court to rule that these patents are invalid and/or should not be     <font color="blue">enforced against</font> that <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>These lawsuits are expensive and would     consume time and other <font color="blue">resources even</font> if we were successful in stopping the     <font color="blue">infringement</font> of these patents</td>
    </tr>
    <tr>
      <td>In addition, there is a risk that the court     will decide that these patents are not valid and that we do not have the     right to stop the other <font color="blue">party from using</font> the <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>There is also the     risk that, even if the validity of these patents is upheld, the <font color="blue">court will</font>     refuse  to  stop the other party on the ground that such other partyapstas     <font color="blue">activities</font> do not infringe our rights to these patents</td>
    </tr>
    <tr>
      <td>Furthermore, a <font color="blue">third party</font> may claim that we are using <font color="blue">inventions</font> <font color="blue">covered by</font>     the <font color="blue">third party</font>apstas patent rights and may go to court to stop us from engaging     in our normal <font color="blue">operations</font> and <font color="blue">activities</font>, including making or selling our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>These lawsuits are costly and <font color="blue">could affect</font> our results     of  <font color="blue">operations</font>  and  divert  the attention of managerial and technical     personnel</td>
    </tr>
    <tr>
      <td>There is a risk that a <font color="blue">court would decide</font> that we are infringing     the <font color="blue">third party</font>apstas patents and would order us to stop the <font color="blue">activities</font> covered     by the patents</td>
    </tr>
    <tr>
      <td>In addition, there is a risk that a <font color="blue">court will</font> order us to     pay the other <font color="blue">party damages</font> for having violated the other partyapstas patents</td>
    </tr>
    <tr>
      <td>The <font color="blue">bio<font color="blue">technology</font></font> industry has produced a <font color="blue">proliferation</font> of patents, and it     is not <font color="blue">always clear</font> to industry <font color="blue">participants</font>, including us, which patents     <font color="blue">cover various types</font> of products or methods of use</td>
    </tr>
    <tr>
      <td>The coverage of patents     is subject to <font color="blue">interpretation</font> by the courts, and the <font color="blue">interpretation</font> is not     <font color="blue">always uniform</font></td>
    </tr>
    <tr>
      <td>If we are sued for patent <font color="blue">infringement</font>, we would need to     <font color="blue">demonstrate</font> that our products or methods of use either do not infringe the     patent claims of the relevant patent and/or that the patent claims are     invalid,  and  we  may  not be able to do this</td>
    </tr>
    <tr>
      <td>Proving <font color="blue">invalidity</font>, in     particular, is <font color="blue">difficult</font> since it requires a showing of clear and convincing     evidence to overcome the <font color="blue">presumption</font> of validity enjoyed by <font color="blue">issued patents</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________           Because some patent <font color="blue">application</font>s in the <font color="blue"><font color="blue">United States</font> of America </font>may be     maintained  in  secrecy  until  the patents are issued, because patent     <font color="blue">application</font>s in the <font color="blue"><font color="blue">United States</font> of America </font>and many foreign <font color="blue">jurisdictions</font>     are typically not published until eighteen months after filing, and because     <font color="blue">publications</font>  in  the  scientific  literature  often lag behind actual     <font color="blue">discoveries</font>,  we  cannot  be certain that others have not filed patent     <font color="blue">application</font>s for <font color="blue">technology</font> <font color="blue">covered by</font> our <font color="blue">licensors</font> &amp;apos  <font color="blue">issued patents</font> or our     pending <font color="blue">application</font>s or our <font color="blue">licensors</font> &amp;apos  pending <font color="blue">application</font>s or that we or     our <font color="blue">licensors</font> were the first to invent the <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> may     have  filed,  and may in the future file, patent <font color="blue">application</font>s covering     <font color="blue">technology</font> similar to ours</td>
    </tr>
    <tr>
      <td>Any such patent <font color="blue">application</font> may have priority     over our or our <font color="blue">licensors</font> &amp;apos  patent <font color="blue">application</font>s and <font color="blue">could further</font> require us     to obtain rights to <font color="blue">issued patents</font> covering such <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If another     party has filed a <font color="blue">United States</font> patent <font color="blue">application</font> on <font color="blue">inventions</font> similar to     ours, we may have to <font color="blue">participate</font> in an <font color="blue">interference proceeding</font> declared by     the <font color="blue">United States</font> Patent and Trademark Office to determine priority of     invention in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The costs of these <font color="blue">proceedings could</font> be     substantial, and it is possible that <font color="blue">such efforts would</font> be <font color="blue">unsuccessful</font>,     resulting in a loss of our <font color="blue">United States</font> patent position <font color="blue">with respect</font> to     such <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> may be able to sustain the costs of complex patent     <font color="blue">litigation</font> more <font color="blue">effective</font>ly than we can because they have <font color="blue">substantially</font>     greater  resources</td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">uncertainties</font> resulting from the     <font color="blue">initiation</font> and <font color="blue">continuation</font> of any <font color="blue">litigation</font> could have a material adverse     effect  on  our  ability  to raise the <font color="blue">funds necessary</font> to continue our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR COMMON STOCK       MARKET  VOLATILITY  MAY  AFFECT  OUR STOCK PRICE AND THE VALUE OF YOUR     INVESTMENT        The <font color="blue"><font color="blue">market price</font>s</font> for securities of bio<font color="blue">pharmaceutical</font> companies in general     have been <font color="blue">highly volatile</font> and <font color="blue">may continue</font> to be <font color="blue">highly volatile</font> in the     future</td>
    </tr>
    <tr>
      <td>The <font color="blue">following factors</font>, in addition to other <font color="blue">risk factors described</font>     in this section, may have a <font color="blue">significant</font> <font color="blue">impact on</font> the <font color="blue">market price</font> of our     <font color="blue">common stock</font>:         ·       <font color="blue">announcement</font>s of <font color="blue">technological innovations</font> or <font color="blue">new products by us</font> or our     <font color="blue">competitors</font>;         ·       <font color="blue">announcement</font> of FDA approval or non-approval of our <font color="blue">product <font color="blue">candidates</font></font> or     delays in the FDA <font color="blue">review process</font>;         ·       actions taken by <font color="blue">regulatory</font> agencies <font color="blue">with respect</font> to our <font color="blue">product <font color="blue">candidates</font></font>,     <font color="blue">clinical trials</font>, <font color="blue"><font color="blue">manufacturing</font> process</font> or sales and marketing <font color="blue">activities</font>;         ·       <font color="blue">regulatory</font> <font color="blue">development</font>s in the <font color="blue"><font color="blue">United States</font> of America </font>and foreign     countries;         ·       the success of our <font color="blue">development</font> efforts and <font color="blue">clinical trials</font>;         ·       the success of our efforts to acquire or in-license <font color="blue">additional</font> products or     <font color="blue">product <font color="blue">candidates</font></font>;         ·       any <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">infringement</font> action, or any other <font color="blue">litigation</font>,     <font color="blue">involving us</font>;         ·       <font color="blue">announcement</font>s concerning our <font color="blue">competitors</font>, or the <font color="blue">bio<font color="blue">technology</font></font> or     bio<font color="blue">pharmaceutical</font> industries in general;         ·       actual or anticipated <font color="blue">fluctuations</font> in our operating results;         ·       changes in financial estimates or <font color="blue">recommendations by securities analysts</font>;         ·       our ability to maintain listing <font color="blue">requirements</font> on the American Stock Exchange;         ·       sales of large blocks of our <font color="blue">common stock</font>;         ·       sales of our <font color="blue">common stock</font> by our executive officers, directors and     <font color="blue">significant</font> <font color="blue">stockholders</font>; and         ·       the loss of any of our <font color="blue">key scientific</font> or <font color="blue"><font color="blue">management</font> personnel</font></td>
    </tr>
    <tr>
      <td>The occurrence of one or more of these <font color="blue">factors may</font> cause our stock price to     decline, and <font color="blue">investors may</font> not be able to resell their shares at or above     the price that they paid for the shares</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock markets</font> in     general, and the markets for <font color="blue">bio<font color="blue">technology</font></font> and bio<font color="blue">pharmaceutical</font> stocks in     particular,  have  experienced  <font color="blue">extreme <font color="blue">volatility</font></font> that has often been     unrelated to the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>These broad     market <font color="blue">fluctuations</font> may <font color="blue">adversely</font> affect the <font color="blue">trading price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>WE ARE AT RISK OF SECURITIES CLASS ACTION LITIGATION        In the past, securities class action <font color="blue">litigation</font> has often been brought     against a company following a decline in the <font color="blue">market price</font> of its securities</td>
    </tr>
    <tr>
      <td>This  risk  is  <font color="blue">especially</font>  relevant  for us because <font color="blue">bio<font color="blue">technology</font></font> and     bio<font color="blue">pharmaceutical</font>  companies  have experienced <font color="blue">significant</font> stock price     <font color="blue">volatility</font> in <font color="blue">recent years</font></td>
    </tr>
    <tr>
      <td>If we faced such <font color="blue">litigation</font>, it could result in     substantial costs and a diversion of <font color="blue">management</font>apstas attention and resources,     <font color="blue">which could harm</font> our business</td>
    </tr>
    <tr>
      <td>WE HAVE NOT PAID CASH DIVIDENDS IN THE PAST AND DO NOT EXPECT TO PAY CASH     DIVIDENDS IN THE FUTURE ANY RETURN ON INVESTMENT MAY BE LIMITED TO THE     VALUE OF OUR STOCK        We have <font color="blue">never paid <font color="blue">cash <font color="blue">dividends on</font></font></font> our stock and do not anticipate paying     <font color="blue">cash <font color="blue">dividends on</font></font> our stock in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The payment of cash     <font color="blue">dividends on</font> our <font color="blue">stock will depend on</font> our earnings, financial condition and     other business and <font color="blue">economic factors affecting us at such</font> time as the board     of <font color="blue">directors may</font> consider relevant</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">pay cash dividends</font>, our     stock may be less valuable because a return on your <font color="blue">investment</font> will only     occur if our stock price appreciates</td>
    </tr>
  </tbody>
</table>